Silver Book Fact

Negative value of antibiotics to drug companies

The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.

Incentives for R&D for New Antimicrobial Drugs: Research paper 11/02. http://www.ohe.org/publications/article/incentives-for-rd-for-new-antimicrobial-drugs-7.cfm. Published 2011

Reference

Title
Incentives for R&D for New Antimicrobial Drugs: Research paper 11/02
Publisher
Office of Health Economics
Publication Date
Published 2011
Authors
Towse A, Sharma P
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Reduction in hospital-acquired HAIs could produce significant savings
    Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
  • Reduction of central-line infections saved ~ 1,800 lives and $280 million
    Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.  
  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.